Articles from Unicycive Therapeutics, Inc.

Appointment adds decades of drug development experience from a seasoned executive

LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer was recently featured on the Nasdaq Amplify Issuer Spotlight interview series. The series explores how industry leaders within small-cap community are evolving and navigating challenges in various industries.

Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease

LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference “Glomerular Disease: IgAN Is Just the Tip of the Iceberg” on Tuesday, July 25, 2023 at 11:00 a.m. ET.

Newly Assigned USAN Name, Oxylanthanum Carbonate, replaces Lanthanum Dioxycarbonate

LOS ALTOS, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today provided an update based on recent interactions with the U.S. Food and Drug Administration (FDA or Agency) concerning the Company’s New Drug Application (NDA) for lanthanum dioxycarbonate (LDC), previously known as Renazorb. LDC is an investigational new drug being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced today that Company CEO, Shalabh Gupta, MD, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET 

Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones

Data highlights the potential safety and reno-protective effect of UNI-494

Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones

$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones

Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT 2023 Conference

Develops Renazorb opportunity in new market for patients with hyperphosphatemia

Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia

Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively

LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the termination of its “at-the-market” equity offering program (the “ATM Offering”) with JonesTrading Institutional Services, LLC as sales agent. The Company elected to terminate the ATM Offering to limit uncertainty and unfavorable dilution for its shareholders.

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol

Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023

Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction

Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA)

Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis

Topline Data Expected by Year End 2022

Multiple Data Presentations Support the Company’s Pipeline of Innovative Product Candidates aimed at Improving the Quality-of-Life for Patients Battling Kidney Disease

Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction